RUBYnanomed was founded in 2018 as a spin-off of INL and aims to bring lab discoveries to the clinical market. Contact us to learn more on how to be part of RUBYnanomed´s passionate team, surrounded by internationally recognised researchers, and fully devoted to improve cancer diagnosis, monitoring and treatment.